Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Cash (2021 - 2025)

Historic Change in Cash for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$7.7 million.

  • Lyra Therapeutics' Change in Cash rose 463.91% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 28755.56%. This contributed to the annual value of $18.8 million for FY2024, which is 28461.31% up from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Change in Cash is -$7.7 million, which was up 463.91% from -$2.0 million recorded in Q2 2025.
  • Lyra Therapeutics' Change in Cash's 5-year high stood at $88.0 million during Q2 2022, with a 5-year trough of -$77.0 million in Q4 2022.
  • Moreover, its 5-year median value for Change in Cash was -$8.1 million (2024), whereas its average is -$2.7 million.
  • Examining YoY changes over the last 5 years, Lyra Therapeutics' Change in Cash showed a top increase of 289228.15% in 2022 and a maximum decrease of 52204.46% in 2022.
  • Over the past 5 years, Lyra Therapeutics' Change in Cash (Quarter) stood at -$12.4 million in 2021, then plummeted by 522.04% to -$77.0 million in 2022, then surged by 96.76% to -$2.5 million in 2023, then soared by 771.93% to $16.8 million in 2024, then crashed by 146.07% to -$7.7 million in 2025.
  • Its last three reported values are -$7.7 million in Q3 2025, -$2.0 million for Q2 2025, and -$8.8 million during Q1 2025.